Dr. Michael Henderson is the CEO of Apogee Therapeutics. He also serves on the company’s board of directors and is a member of the board of managers. He is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy, having overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date.
Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies, and running business development and operations. Dr. Henderson also served in leadership positions for several prominent subsidiary companies of BridgeBio.
Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, before which he co-founded PellePharm, Inc., a biotechnology company. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.
What is Michael Thomas Henderson's net worth?
The estimated net worth of Michael Thomas Henderson is at least $6.75 million as of May 8th, 2026. Dr. Henderson owns 88,606 shares of Spyre Therapeutics stock worth more than $6,749,030 as of May 11th. This net worth approximation does not reflect any other investments that Dr. Henderson may own. Learn More about Michael Thomas Henderson's net worth.
How do I contact Michael Thomas Henderson?
Has Michael Thomas Henderson been buying or selling shares of Spyre Therapeutics?
During the past quarter, Michael Thomas Henderson has sold $5,952,000.00 in shares of Spyre Therapeutics stock. Most recently, Michael Thomas Henderson sold 80,000 shares of the business's stock in a transaction on Friday, May 8th. The shares were sold at an average price of $74.40, for a transaction totalling $5,952,000.00. Following the completion of the sale, the director now directly owns 88,606 shares of the company's stock, valued at $6,592,286.40. Learn More on Michael Thomas Henderson's trading history.
Who are Spyre Therapeutics' active insiders?
Are insiders buying or selling shares of Spyre Therapeutics?
In the last twelve months, insiders at the sold shares 14 times. They sold a total of 342,219 shares worth more than $18,494,848.78. The most recent insider tranaction occured on May, 8th when Director Michael Thomas Henderson sold 80,000 shares worth more than $5,952,000.00. Insiders at Spyre Therapeutics own 15.7% of the company.
Learn More about insider trades at Spyre Therapeutics. Information on this page was last updated on 5/8/2026.
